RESULTS. The rate of pertussis immunization was the same in both groups (65.2% cases versus 68.9% controls, P 5 .172). Nearly 80% of cases were younger than 18 years old (mean 5 13.9 years). Sixty-two (38%) patients with pertussis and 85 (26%) controls had asthma before the date of pertussis testing (odds ratio [OR] 1.83, P 5 .005). On the basis of the adjusted OR, the population attributable risk percentage of asthma for the risk of pertussis was 17% for all subjects. Antibiotic use and family history of asthma approached, but did not reach, statistical significance between groups. After adjusting for those variables, a history of asthma before the index date of pertussis PCR was still significantly associated with the risk of pertussis (OR 1.73, P 5 .013). Age stratification analysis showed that the association between asthma and increased risk of pertussis was present only in children and adolescents. The use of oral or inhaled corticosteroids did not affect pertussis risk.
CONCLUSIONS. Asthma is associated with an increased risk of pertussis. Given the high incidence of asthma, relatively low pertussis immunization rates, and the increased attributable risk of asthma for pertussis infection, patients with asthma should be a target group for primary pertussis vaccination and for appropriate boosters. REVIEWER COMMENTS. It is possible that altered innate or acquired immunity and/or altered airway epithelium increase the risk of pertussis infection in patients with asthma. The authors were not able to assess asthma control, so they were unable to correlate asthma control with risk of pertussis infection. One can speculate that poorly controlled asthma with greater airway inflammation increases the risk of pertussis (and other airway infections). This study does not change the need to enhance overall immunization rates or the need to monitor and maintain asthma control carefully. It does, however, provide a little more incentive to do both. inhaled glucocorticoids in children at risk for asthma exacerbations.
STUDY POPULATION. Children (n 5 278) in the study were between the ages of 12 and 53 months with positive values on the modified asthma predictive index (API), recurrent wheezing episodes, and at least 1 exacerbation in the previous year, but a low degree of impairment. Children were excluded from the study if they had received more than 6 courses of oral glucocorticoids or had been hospitalized more than 2 times for wheezing during the previous year.
METHODS. The subjects were randomly assigned to receive budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) with corresponding placebos. The primary outcome measure was the frequency of exacerbations requiring oral glucocorticoids.
RESULTS. The daily regimen of budesonide did not differ significantly from the intermittent regimen with respect to the frequency of exacerbations, with a rate per patientyear for the daily regimen of 0.97 versus a rate of 0.95 for the intermittent regimen. There were also no significant differences between the groups in other measures, including the time to the first exacerbation, quality of life, and adverse events; however, the mean exposure to budesonide was 104 mg less with the intermittent regimen than with the daily regimen.
CONCLUSIONS.
A daily low-dose regimen of budesonide was not superior to an intermittent high-dose regimen in reducing asthma exacerbations. Daily administration led to greater exposure to the drug at 1 year.
REVIEWER COMMENTS. This well-designed and interesting study will help to change how we treat asthma in children; however, it is important to understand that these results are applicable only to children who fulfill the strictly defined criteria of this trial. For example, these results do not apply to children whose asthma is more severe or children who do not have positive values on the API. Another important consideration is that the intermittent regimen used in this trial (with the secondary result of reduced exposure to budesonide) involved treating with high-dose budesonide only at the onset of predefined respiratory tract illnesses on the basis of individualized symptoms that historically had occurred before the onset of wheezing. This reduced the exposure to budesonide to once every 3.5 months on average, in contrast to the approximately monthly exposure that would be anticipated to be required when such therapy would be started indiscriminately with each upper respiratory tract infection. This approach demands careful, individualized instruction. With these caveats taken into account, physicians may have 2 reasonable approaches to treatment to consider in treating this group of pediatric patients. STUDY POPULATION. A total of 249 children (Tanner stage #1) aged 4 to 10 years, with mild intermittent asthma, were randomized to flunisolide hydrofluoroalkane (HFA) (n 5 122) or to placebo (n 5 127). At study completion, 218 met criteria for inclusion in efficacy analysis (at least 3 measurements of post-baseline height).
METHODS. This was a multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. During a 2-week run-in period, during which albuterol was allowed for symptoms, compliance with study procedures, baseline symptom scores, and need for inhaled corticosteroids was obtained. Subjects were randomized 1:1 to 2 puffs flunisolide HFA (85 mg/puff) twice daily or 2 puffs placebo twice daily. The primary end point was growth velocity assessed by regression analysis estimated for each eligible subject by the slope of the linear regression of stadiometric height over time, expressed as cm/52 weeks. The secondary end point was change from baseline to week 53 in radiographic bone age based on bone maturation in the hand and wrist.
RESULTS. Flunisolide HFA 2 puffs twice daily for 1 year compared with placebo did not affect growth velocity (6.01 6 1.84 cm/52 weeks versus 6.19 6 1.30 cm/52 weeks, P 5 .425), mean change in height (6.14 6 2.12 cm versus 6.31 6 1.26 cm, P 5 .343), or bone maturation (0.93 6 0.46 vs 1.01 6 0.41, P 5 .128) in children with mild persistent asthma.
CONCLUSIONS. One year of chronic use of flunisolide HFA (85 mg/puff) for the treatment of mild persistent asthma did not suppress growth or bone maturation at the highest approved dose.
REVIEWER COMMENTS. The topic of growth suppression with inhaled corticosteroids is an important concern for
